What Is Liraglutide? A Plain-Language Guide to the Daily GLP-1 Medication

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Liraglutide is a once-daily injectable GLP-1 receptor agonist used to treat type 2 diabetes (brand name Victoza) and chronic weight management (brand name Saxenda).
• It was the first FDA-approved daily GLP-1 medication for weight loss, approved by the FDA in 2014 for that indication.
• Average weight loss in clinical trials was about 8% of body weight at the 3.0 mg dose over 56 weeks (Pi-Sunyer et al., NEJM 2015).
• It works by mimicking the natural gut hormone GLP-1, which slows gastric emptying, increases insulin response, and reduces appetite.
• Newer once-weekly GLP-1 drugs (semaglutide, tirzepatide) generally produce more weight loss, but liraglutide remains an option for patients who tolerate it better or have insurance coverage limited to it.

Direct answer (40-60 words)

Liraglutide is a daily injectable medication that mimics the gut hormone GLP-1. It is sold under the brand names Victoza for type 2 diabetes and Saxenda for chronic weight management. It lowers blood sugar, slows stomach emptying, and reduces appetite. It was the first GLP-1 approved by the FDA for weight loss, in 2014.

Table of contents

1. The 30-second answer
2. The science: what GLP-1 does in the body
3. Brand names and approved uses
4. How liraglutide is taken
5. Dosing schedule for diabetes vs weight loss
6. Effectiveness: what the trials show
7. Side effects, common and serious
8. Who should not take liraglutide
9. Liraglutide vs other GLP-1 medications
10. Cost, coverage, and generic status
11. FAQ
12. Sources

The science: what GLP-1 does in the body

GLP-1 (glucagon-like peptide-1) is a hormone made by L cells in the small intestine. It is released after meals and does several things:

• Tells the pancreas to release more insulin in response to food (glucose-dependent, so it does not cause hypoglycemia at typical levels).
• Tells the pancreas to release less glucagon, the hormone that raises blood sugar.
• Slows the stomach from emptying its contents into the intestine.
• Acts on the brain (hypothalamus and brainstem) to reduce appetite and increase satiety.

Natural GLP-1 has a half-life of about 2 minutes because an enzyme called DPP-4 breaks it down rapidly. That makes natural GLP-1 useless as a medication. Liraglutide is a modified version of GLP-1 with two changes: a fatty acid chain that lets it bind reversibly to albumin in the blood (slowing clearance), and a single amino acid substitution that resists DPP-4 cleavage. The result is a half-life of about 13 hours, which makes once-daily dosing feasible (Knudsen et al., Journal of Medicinal Chemistry 2000).

Brand names and approved uses

Liraglutide is the generic chemical name. Two FDA-approved brand-name products contain it:

The two products contain the same active drug at different concentrations and label different titration schedules. Saxenda is also approved for adolescents aged 12 to 17 with obesity, with a 2020 label expansion. Victoza is approved down to age 10 for type 2 diabetes (Tamborlane et al., NEJM 2019).

Both products are made by Novo Nordisk. The U.S. patent on liraglutide expired in 2023, which has cleared the way for generic and authorized-generic versions.

How liraglutide is taken

Liraglutide is a daily subcutaneous injection. It comes in a multi-dose pen that the patient dials and self-injects. The injection sites are the abdomen, the front of the thigh, or the upper arm. The dose can be taken at any time of day, with or without food, but most patients take it at the same time daily for habit consistency.

The needle is a standard pen needle (32-gauge, 4 to 5 mm). The pen is stored refrigerated before first use and at room temperature (not above 86°F) for up to 30 days after first use.

Unlike semaglutide and tirzepatide, liraglutide is not available as a once-weekly injection. The shorter half-life means daily dosing is required.

Dosing schedule for diabetes vs weight loss

The dosing curves are different because the drug behaves differently at higher doses for weight loss than for glucose control.

Victoza (type 2 diabetes):

• Week 1: 0.6 mg/day (titration dose, not therapeutic)
• Week 2 onward: 1.2 mg/day
• May escalate to 1.8 mg/day if blood sugar control is inadequate

Saxenda (weight management):

• Week 1: 0.6 mg/day
• Week 2: 1.2 mg/day
• Week 3: 1.8 mg/day
• Week 4: 2.4 mg/day
• Week 5 onward: 3.0 mg/day

The slow titration is to reduce nausea and other GI side effects, which are dose-dependent and typically peak in the first 4 to 8 weeks.

Effectiveness: what the trials show

For type 2 diabetes (LEAD trials, 2009-2010): liraglutide 1.8 mg daily reduced HbA1c by about 1.0 to 1.5 percentage points, depending on the comparator. Average weight loss was 2 to 3 kg. Cardiovascular outcomes were favorable in the LEADER trial (Marso et al., NEJM 2016), which showed a 13% reduction in major adverse cardiovascular events vs placebo over 3.8 years.

For weight loss (SCALE trials, 2015): liraglutide 3.0 mg daily produced an average weight loss of 8.0% from baseline at 56 weeks vs 2.6% with placebo (Pi-Sunyer et al., NEJM 2015). About 63% of patients lost at least 5% of body weight, and 33% lost at least 10%. The SCALE Diabetes trial in patients with type 2 diabetes showed slightly less weight loss (about 6%), as is typical for weight loss medications in diabetic patients.

For comparison, the SURMOUNT-1 trial of tirzepatide (Jastreboff et al., NEJM 2022) showed an average weight loss of about 22.5% at the 15 mg dose at 72 weeks. The STEP 1 semaglutide trial (Wilding et al., NEJM 2021) showed about 14.9% at 68 weeks. Liraglutide produces meaningful weight loss but less than the newer once-weekly options.

Side effects, common and serious

Common (greater than 5% in trials):

• Nausea (around 39% in SCALE)
• Diarrhea (21%)
• Constipation (19%)
• Vomiting (16%)
• Headache (14%)
• Decreased appetite (10%)
• Dyspepsia (9%)
• Fatigue (8%)
• Injection site reactions

Most GI side effects are dose-dependent and improve after 4 to 8 weeks of consistent use. They are worst during titration.

Serious (rare but boxed warning):

• Thyroid C-cell tumors. Boxed warning based on rodent studies showing medullary thyroid carcinoma. Whether this translates to humans is uncertain, but liraglutide is contraindicated in patients with personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
• Pancreatitis. Cases reported in trials and post-marketing. Patients with persistent severe abdominal pain should stop the drug and seek evaluation.
• Acute kidney injury, often related to dehydration from prolonged vomiting or diarrhea.
• Hypoglycemia, primarily when combined with insulin or sulfonylureas in diabetes treatment.
• Gallbladder disease, including cholelithiasis and cholecystitis.
• Suicidal ideation. The FDA reviewed this signal in 2024 and concluded the data did not support a causal link, but it remains under monitoring.

Who should not take liraglutide

Absolute contraindications:

• Personal or family history of medullary thyroid carcinoma
• Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)
• Known hypersensitivity to liraglutide or pen excipients
• Pregnancy (Saxenda for weight loss specifically; the medication should be discontinued)

Use with caution:

• History of pancreatitis
• Severe gastroparesis
• Severe renal impairment (eGFR less than 30)
• Type 1 diabetes (it is not approved for type 1)
• Concurrent insulin or sulfonylurea use (hypoglycemia risk)

Liraglutide vs other GLP-1 medications

Quick comparison of the major GLP-1 and GLP-1 / GIP medications:

The trade-offs for liraglutide vs the newer drugs:

• Liraglutide pros: longest safety record (since 2010), pediatric approval at age 10 for diabetes and age 12 for weight loss, available in some pediatric and pregnancy-considered protocols where newer drugs are not. Now off-patent, so generic versions are appearing.
• Liraglutide cons: daily injection, more total injections per year, less weight loss than once-weekly options. GI side effects are similar in profile but distributed across more frequent dosing.

Cost, coverage, and generic status

Brand-name Saxenda runs about $1,300 to $1,400 per month at U.S. retail pharmacies as of early 2026. Victoza is similarly priced. Insurance coverage for the diabetes indication (Victoza) is broader than coverage for the weight loss indication (Saxenda), where many commercial plans exclude weight management drugs.

The U.S. patent on liraglutide expired in 2023. Several authorized-generic and bioequivalent versions have entered the U.S. market. Generic liraglutide is currently priced at roughly half to two-thirds the brand-name cost, though pricing varies significantly by pharmacy and program.

Compounded liraglutide is not as common as compounded semaglutide and tirzepatide. The FDA permitted compounded semaglutide and tirzepatide during a labeled shortage period; liraglutide has not been on the FDA's drug shortage list. Compounded liraglutide is therefore harder to source legally and is generally not the preferred compounded GLP-1 option.

For patients exploring compounded GLP-1 therapy, semaglutide and tirzepatide remain the two compounds with the clearest pharmacy and clinical infrastructure. (See our compounded semaglutide guide and tirzepatide cost guide for current pricing.)

FAQ

What is liraglutide? Liraglutide is a daily injectable GLP-1 receptor agonist medication. It is sold as Victoza for type 2 diabetes and Saxenda for chronic weight management. It mimics the natural gut hormone GLP-1, lowering blood sugar, slowing stomach emptying, and reducing appetite.

What is liraglutide used for? Liraglutide treats type 2 diabetes (under the brand name Victoza) and chronic weight management in adults with BMI 30 or higher, or BMI 27 or higher with a weight-related condition like high blood pressure or sleep apnea (under the brand name Saxenda). Saxenda is also approved for adolescents aged 12 to 17 with obesity.

How does liraglutide work? Liraglutide binds to the GLP-1 receptor in the pancreas, brain, and gastrointestinal tract. It increases insulin release after meals, decreases glucagon release, slows gastric emptying, and signals satiety in the brain. The combination reduces blood sugar and appetite.

How is liraglutide taken? Liraglutide is injected subcutaneously once daily, in the abdomen, thigh, or upper arm. It comes in a multi-dose pen. The dose is titrated up over 5 weeks (for weight loss) or 1 to several weeks (for diabetes) to reduce nausea.

How much weight do people lose on liraglutide? In the SCALE clinical trial, patients on Saxenda 3.0 mg daily lost an average of 8% of body weight at 56 weeks, compared to 2.6% with placebo (Pi-Sunyer et al., NEJM 2015). About 63% lost at least 5% of body weight.

What are the side effects of liraglutide? The most common side effects are nausea, diarrhea, constipation, vomiting, headache, and decreased appetite. Most are mild to moderate and improve after the first 4 to 8 weeks. Serious but rare risks include pancreatitis, gallbladder disease, thyroid C-cell tumors (boxed warning), and acute kidney injury from dehydration.

Is liraglutide the same as Ozempic? No. Ozempic is brand-name semaglutide, a different GLP-1 medication taken once weekly. Liraglutide (Victoza, Saxenda) is taken daily. Both are GLP-1 receptor agonists, but they are distinct molecules with different half-lives and different dosing schedules. Semaglutide produces more weight loss in head-to-head trials.

Is liraglutide the same as Saxenda or Victoza? Liraglutide is the generic chemical name. Saxenda and Victoza are brand-name products that contain liraglutide. Saxenda is dosed up to 3.0 mg daily for weight loss. Victoza is dosed up to 1.8 mg daily for type 2 diabetes.

Who should not take liraglutide? People with personal or family history of medullary thyroid carcinoma, Multiple Endocrine Neoplasia syndrome type 2, severe pancreatitis history, severe gastroparesis, or known hypersensitivity to liraglutide. Use is also avoided during pregnancy and in patients with severe kidney impairment.

How long does it take liraglutide to work? Blood sugar effects are measurable within the first 1 to 2 weeks. Appetite suppression typically begins in the first week but builds with dose escalation. Meaningful weight loss is generally visible by week 8 to 12, with maximum effect by week 56.

Can you stop liraglutide once you reach your weight loss goal? Stopping liraglutide typically leads to weight regain. The SCALE Maintenance trial showed that patients who stopped after 56 weeks regained about two-thirds of their lost weight over the following year. Most clinicians treat obesity as a chronic condition requiring ongoing therapy.

Is liraglutide available as a generic? Yes. The liraglutide patent expired in 2023, and generic and authorized-generic liraglutide products have entered the U.S. market. Pricing is typically lower than brand-name Saxenda or Victoza but varies by pharmacy.

Sources

1. Pi-Sunyer X, et al. A randomized, controlled trial of 3.0 mg of liraglutide in weight management. N Engl J Med. 2015;373:11-22.
2. Marso SP, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes (LEADER trial). N Engl J Med. 2016;375:311-322.
3. Knudsen LB, et al. Potent derivatives of glucagon-like peptide-1 with pharmacokinetic properties suitable for once daily administration. J Med Chem. 2000;43:1664-1669.
4. Tamborlane WV, et al. Liraglutide in children and adolescents with type 2 diabetes. N Engl J Med. 2019;381:637-646.
5. Davies MJ, et al. Efficacy of liraglutide for weight loss among patients with type 2 diabetes (SCALE Diabetes). JAMA. 2015;314:687-699.
6. Wadden TA, et al. Weight maintenance and additional weight loss with liraglutide after low-calorie diet (SCALE Maintenance). Int J Obes. 2013;37:1443-1451.
7. Wilding JPH, et al. Once-weekly semaglutide in adults with overweight or obesity (STEP 1). N Engl J Med. 2021;384:989-1002.
8. Jastreboff AM, et al. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). N Engl J Med. 2022;387:205-216.
9. Saxenda (liraglutide) Prescribing Information. Novo Nordisk Inc. Updated 2024.
10. Victoza (liraglutide) Prescribing Information. Novo Nordisk Inc. Updated 2024.
11. American Diabetes Association. Standards of Care in Diabetes 2024. Diabetes Care. 2024;47(Suppl 1).
12. Garvey WT, et al. AACE/ACE clinical practice guidelines for medical care of patients with obesity. Endocr Pract. 2016;22(Suppl 3):1-203.
13. FDA Drug Safety Communication on GLP-1 receptor agonists and suicidal thoughts. 2024.
14. Kelly AS, et al. Liraglutide for adolescents with obesity. N Engl J Med. 2020;382:2117-2128.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Saxenda, Victoza, Ozempic, Wegovy, Rybelsus, Trulicity, Mounjaro, Zepbound, Byetta, and Bydureon are registered trademarks of their respective owners. FormBlends is not affiliated with, endorsed by, or sponsored by Novo Nordisk, Eli Lilly, or AstraZeneca.